Home > Insider Trading > Filing (0000947871-18-000156)

Filing Details

Accession Number:: 0000947871-18-000156
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-02-15 16:57:01
Reporting Period:: 2018-02-13

Accepted Time:: 2018-02-15 16:57:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1583648	Pieris Pharmaceuticals Inc.	PIRS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No
1432241	Orbimed Capital Gp Iii Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-02-13	6,057	$4.68	5,506,787	No	4	M	Indirect	See Footnotes
Common Stock	Acquisiton	2018-02-13	58	$4.68	49,328	No	4	M	Indirect	See Footnotes
Common Stock	Acquisiton	2018-02-13	1,765	$5.08	5,508,552	No	4	M	Indirect	See Footnotes
Common Stock	Acquisiton	2018-02-13	17	$5.08	49,345	No	4	M	Indirect	See Footnotes
Common Stock	Disposition	2018-02-13	7,822	$8.98	5,500,730	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2018-02-13	75	$8.98	49,270	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See Footnotes
No	4	M	Indirect	See Footnotes
No	4	M	Indirect	See Footnotes
No	4	M	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-02-13	6,057	$0.00	6,057	$4.68
Common Stock	Stock Option (right to buy)	Disposition	2018-02-13	58	$0.00	58	$4.68
Common Stock	Stock Option (right to buy)	Disposition	2018-02-13	1,765	$0.00	1,765	$5.08
Common Stock	Stock Option (right to buy)	Disposition	2018-02-13	17	$0.00	17	$5.08

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2018-02-15	No	4	M	Indirect
2018-02-15	No	4	M	Indirect
2018-02-15	No	4	M	Indirect
2018-02-15	No	4	M	Indirect

Footnotes

The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on October 25, 2017 for services as a director of the Issuer. The award included stock options relating to a total of 6,115 shares of the Issuer's Common Stock and was vested and exercisable on October 25, 2017. Mr. Khuong is no longer a director of the Issuer.
The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on January 25, 2018 for services as a director of the Issuer. The award included stock options relating to a total of 1,782 shares of the Issuer's Common Stock and was vested and exercisable on January 25, 2018. Mr. Khuong is no longer a director of the Issuer.
These Shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III.
These Shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. By virtue of such relationships, Advisors may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by Associates III.
Samuel D. Isaly, who was included as a Reporting Person on previous reports under Section 16 of the Exchange Act filed by GP III and Advisors, is no longer subject to Section 16 with respect to securities of the Issuer.
This report on Form 4 is jointly filed by GP III and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.